OncoCyte Corporation
OCX
$2.73
$0.083.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 43.88% | 1,192.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 43.88% | 1,192.17% | |||
| Cost of Revenue | -7.25% | 1,920.93% | |||
| Gross Profit | 115.88% | 756.94% | |||
| SG&A Expenses | 14.89% | 4.24% | |||
| Depreciation & Amortization | -68.18% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.43% | 6.46% | |||
| Operating Income | -7.63% | 14.93% | |||
| Income Before Tax | 80.09% | -148.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 80.09% | -148.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 80.09% | -148.36% | |||
| EBIT | -7.63% | 14.93% | |||
| EBITDA | -10.00% | 19.47% | |||
| EPS Basic | 86.53% | -95.94% | |||
| Normalized Basic EPS | 27.20% | 34.09% | |||
| EPS Diluted | 86.51% | -95.94% | |||
| Normalized Diluted EPS | 27.20% | 34.09% | |||
| Average Basic Shares Outstanding | 47.82% | 26.75% | |||
| Average Diluted Shares Outstanding | 47.82% | 26.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||